{"title": "ARTICLE Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp", "abstract": "", "autors": [{"firstname": "Xiangguo", "middlename": "", "surname": "Qiu1"}, {"firstname": "Gary", "middlename": "", "surname": "Wong1"}, {"firstname": "Jonathan", "middlename": "", "surname": "Audet1"}, {"firstname": "Alexander", "middlename": "", "surname": "Bello1"}, {"firstname": "Lisa", "middlename": "", "surname": "Fernando1"}, {"firstname": "Judie", "middlename": "B", "surname": "Alimonti1"}, {"firstname": "Hugues", "middlename": "", "surname": "Fausther-Bovendo1"}, {"firstname": "Haiyan", "middlename": "", "surname": "Wei1"}, {"firstname": "Jenna", "middlename": "", "surname": "Aviles1"}, {"firstname": "Ernie", "middlename": "", "surname": "Hiatt4"}, {"firstname": "Ashley", "middlename": "", "surname": "Johnson4"}, {"firstname": "Josh", "middlename": "", "surname": "Morton4"}, {"firstname": "Kelsi", "middlename": "", "surname": "Swope4"}], "blocks": [{"title": "", "sequence": "", "paragraphs": [["| Efficacy of individual and combined monoclonal antibody treatments in guinea pigs and nonhuman primates Treatment groups, time of treatment Dose P value, compared with", "cZMAb MB-003 Guinea pigs 2 2 Nonhuman primates.", "Survival and weight loss were monitored over 28 days.", "Treatment with c13C6 or", "h13F6 yielded 17% survival with a mean time to death of 8.4 6 1.7 and 10.2 6 1.8 days, respectively.", "The average weight loss for c13C6 or h13F6-treated animals was 9% and 21%.", "In nonhuman primates, animals were given three doses of mAb c13C6, h13F6 or c6D8, beginning at 24 h after challenge with the Kikwit variant of EBOV 18, and survival was monitored over 28 days.", "Only c13C6 treatment yielded any survivors, with 1 of 3 animals protected from EBOV challenge, confirming in two separate animal models that c13C6 is the component that provides the highest level of protection in the MB-003 cocktail.", "We then tested mAb c13C6 in combination with two of three mAbs from ZMAb in guinea pigs.", "The individual antibodies composing ZMAb were originally chosen for protection studies based on their in vivo protection of guinea pigs against EBOV-M-GPA19, and all three possible combinations were tested: ZMapp1, ZMapp2, and compared to the originator cocktails ZMAb and MB-003.", "Three days after a Group A Group B Group C b c d i m Days post-infection Days post-infection", "Days post-infection", "Days post-infection | Post-exposure protection of EBOV-infected nonhuman primates with ZMapp1 and ZMapp2.", "Rhesus macaques were challenged with EBOV-K, and 50 mg kg21 of ZMapp1 were administered on days 3, 6, and 9.", "Surviving animals showed only mild signs of disease, Died, 6 dpi Hypothermia was defined as below", "35 uC. Fever was defined as .1.0 uC higher than baseline.", "Mild rash was defined as focal areas of petechiae covering ,10% of the skin, moderate rash as areas of petechiae covering 10 to 40% of the skin, and severe rash as areas of petechiae and/or ecchymosis covering .40% of the skin.", "Leukocytopenia and thrombocytopenia were defined as a .30% decrease in numbers of white blood cells and platelets, respectively.", "Leukocytosis and thrombocytosis were defined as a twofold or greater increase in numbers of white blood cells and platelets over baseline, where white blood cell count.", "11 3 103.", "\"", ", two-to threefold increase; \"\", four-to fivefold increase; \"\"\", greater than fivefold increase; #, two-to threefold decrease; ##, four-to fivefold decrease; ###, greater than fivefold decrease.", "ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMY, amylase; TBIL, total bilirubin;", "BUN, blood urea nitrogen; PHOS, phosphate; CRE, creatinine; GLU, glucose; GLOB, globulin."]]}, {"title": "ARTICLE RESEARCH", "sequence": "", "paragraphs": []}, {"title": "RESEARCH ARTICLE 2014 Macmillan Publishers Limited. All rights reserved", "sequence": "", "paragraphs": [["Platelets per mm3 in addition to a drastic drop in body temperature shortly before death.", "At the time of death, animal B3 had elevated levels of alanine aminotransferase, total bilirubin, blood urea nitrogen and creatinine, in addition to decreased levels of glucose, suggesting multiple organ failure.", "All six Group B animals showed fever in addition to viraemia at 3 dpi by TCID50 and RT qPCR.", "It was interesting to note that in B3, the viraemia reached approximately 106 TCID50 after 3 dpi, suggesting that this NHP was particularly susceptible to EBOV infection.", "No escape mutants were detected with this animal.", "The administration of ZMapp2 at the reported concentrations was unable to effectively control viraemia at this level.", "Virus shedding was also detected from the oral and rectal swabs by RT qPCR in the moribund NHP B3.", "Since ZMapp1 demonstrated superior protection to ZMapp2 in this survival study, ZMapp1 was carried forward to test the limits of protection conferred by this mAb cocktail in a subsequent investigation.", "ZMapp-treated NHPs", "In this experiment, rhesus macaques were assigned into three treatment groups of six and a control group of three animals, with all treatment NHPs receiving three doses of ZMapp, and total bilirubin indicate significant liver damage, a hallmark of filovirus infections.", "However, ZMapp was successful in reversing observed disease symptoms and physiological abnormalities after 12 dpi, 2 days after the last ZMapp administration.", "Furthermore, ZMapp treatment was able to lower the high virus loads observed in animals F2 and F5 (up to 106 TCID50 ml undetectable levels by 14 dpi.", "ZMapp cross-reacts with Guinea EBOV", "Although the results were very promising with EBOV-K-infected NHPs, it was unknown whether therapy with ZMapp would be similarly effective against the Guinean variant of EBOV, the virus responsible for the West African outbreak.", "Direct comparison of published amino acid sequences between EBOV-G and EBOV-K showed that the epitopes targeted by ZMapp20,21 were not mutated between the two virus variants, indicating that the antibodies should retain their specificity for the viral glycoprotein.", "To confirm this, in vitro assays were carried out to compare the binding affinity of c13C6, c2G4 and c4G7 to sucrosepurified EBOV-G and EBOV-K.", "As measured by enzyme-linked immunosorbent assay, the ZMapp components showed slightly better binding kinetics for EBOV-G than for EBOV-K. Additionally, the neutralizing activity of individual mAbs was evaluated in the absence of complement for c2G4 and c4G7, and in the presence of complement for c13C6, as they have previously been shown to neutralize EBOV only under these conditions13.", "The results supported the ELISA binding data, with comparable neutralizing activities between the two viruses."]]}, {"title": "RESEARCH", "sequence": "", "paragraphs": []}, {"title": "Discussion", "sequence": "", "paragraphs": [["The West African outbreak of 2014 has highlighted the troubling absence of available vaccine or therapeutic options to save thousands of lives and stop the spread of EBOV.", "The lack of a clinically acceptable treatment offers limited incentive for people who suspect they might be infected to report themselves for medical help.", "Several previous studies have showed that antibodies are crucial for host survival from EBOV22 24.", "Prior NHP studies have also demonstrated that the ZMAb cocktail could protect 100% or 50% of animals when dosing was initiated 1 or 2 dpi, while the MB-003 cocktail protected 67% of animals with the same dosing regimen.", "Before the success with monoclonal-antibody-based therapies, other candidate therapeutics had only demonstrated efficacy when given within 60 min of EBOV exposure.", "Our results with ZMapp, a cocktail comprising of individual monoclonal antibodies selected from MB-003 and ZMAb, demonstrate for the first time the successful protection of NHPs from EBOV disease when intervention was initiated as late as 5 dpi.", "In the preceding ZMapp1/ ZMapp2 experiment, 11 out of 12 treated animals had detectable fever, and live virus could be detected in the blood of 11 out of 12 animals by 3 dpi.", "Therefore, for the majority of these animals, treatment was therapeutic   bode well for treating EBOV-G infections with ZMapp.", "Since the host antibody response is known to correlate with and is required for protection from EBOV infections23,24, monoclonal-antibodybased treatments are likely to form the centrepiece of any future therapeutic strategies for fighting EBOV outbreaks.", "However, whether ZMapp-treated survivors can be susceptible to re-infection is unknown.", "In a previous study of murine ZMAb-treated, EBOV-challenged NHP survivors, a rechallenge of these animals with the same virus at 10 and 13 weeks after initial challenge yielded 6 of 6 survivors and 4 of 6 survivors, respectively27.", "While specific CD4 1 and CD8 1 T-cell responses could be detected in all animals, the circulating levels of glycoprotein -specific IgG were shown to be tenfold lower in non-survivors compared to survivors, suggesting that antibody levels may be indicative of protective immunity27.", "Sustained immunity with experimental EBOV vaccines in NHPs remains unknown; however, in a recent study, a decrease in GP-specific IgG levels due to old age or a suboptimal reaction to the VSVDG/EBOVGP vaccine in rodents also seem to be indicative of non-survival28.", "ZMapp consists of a cocktail of highly purified monoclonal antibodies; which constitutes a less controversial alternative than whole-blood transfusions from convalescent survivors, as was performed during the 1995 EBOV outbreak in Kikwit29.", "The safety of monoclonal antibody therapy is well documented, with generally low rates of adverse reactions, the capacity to confer rapid and specific immunity in all populations, including the young, the elderly and the immunocompromised, and if necessary, the ability to provide higher-than-natural levels of immunity compared to vaccinations30.", "The evidence presented here suggests that ZMapp offers the best option of the experimental therapeutics currently in development for treating EBOV-infected patients.", "We hope that initial safety testing in humans will be undertaken soon, preferably within the next few months, to enable the compassionate use of ZMapp as soon as possible.", "Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections", "appear only in the online paper."]]}]}